Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_assertion type Assertion NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_head.
- NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_assertion description "[Primary screening with HC2 generally detects 23% (95% confidence interval, CI: 13-23%) more CIN-2, CIN-3, or cancer compared to cytology at cut-off atypical squamous cells of undetermined significance (ASCUS) or LSIL, but is 6% (95% CI: 4-8%) less specific.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_provenance.
- NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_assertion evidence source_evidence_literature NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_provenance.
- NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_assertion SIO_000772 16950021 NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_provenance.
- NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_assertion wasDerivedFrom befree-20140225 NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_provenance.
- NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_assertion wasGeneratedBy ECO_0000203 NP441432.RAYMZgxxxA6ZfxZyPhPNEYxTU_Nl3zKsTnEIZndAzwmdk130_provenance.